In terms of absolute numbers, anti-AChR is the most common subtype of MG overall. However, a greater proportion of patients with refractory MG are anti-MuSK-positive compared with those who are anti-AChR-positive.
There is indeed heterogeneity in disease course and treatment response based on patient antibody profile. Patients with anti–MuSK-positive antibodies appear to be less responsive to conventional treatment than both patients with anti–AChR-positive antibodies and patients without detectable antibodies.
Learn more about MG.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Raghav Govindarajan. Fast Five Quiz: Refractory Myasthenia Gravis - Medscape - Oct 13, 2021.